Cochrane · systematic review · CD006681
Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization
Zee, AAG, van Lieshout, K, van der Heide, M, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 16.7%Very low 0 · 0%Low 4 · 66.7%Moderate 1 · 16.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Low molecular weight heparin compared to no prophylaxis or placebo in prevention of venous thromboembolism in patients with lower‐limb immobilization
Population: prevention of venous thromboembolism in patients with lower‐limb immobilization
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Deep venous thrombosis Low molecular weight heparin vs no prophylaxis or placebo | OR 0.45 [0.33, 0.61] | 7 studies · 1676 participants | Moderate Downgraded: risk of bias |
Pulmonary embolism Low molecular weight heparin vs no prophylaxis or placebo | OR 0.5 [0.17, 1.47] | 5 studies · 2517 participants | Low Downgraded: risk of bias, imprecision |
Symptomatic venous thromboembolism Low molecular weight heparin vs no prophylaxis or placebo | OR 0.4 [0.21, 0.76] | 6 studies · 2924 participants | Low Downgraded: risk of bias, imprecision |
Mortality due to pulmonary embolism Low molecular weight heparin vs no prophylaxis or placebo | no estimate extracted | 8 studies · 3111 participants | Ungraded |
Mortality due to other causes Low molecular weight heparin vs no prophylaxis or placebo | OR 0.33 [0.01, 8.15] | 8 studies · 3111 participants | Low Downgraded: imprecision |
Adverse outcomes Low molecular weight heparin vs no prophylaxis or placebo | OR 2.01 [0.83, 4.86] | 8 studies · 3178 participants | Low Downgraded: risk of bias, imprecision |